NEJM: Latest Research & Medical Advances

The landscape of treatment for locally advanced or metastatic urothelial cancer—cancer of the bladder and urinary tract—is evolving with emerging data on the combination of enfortumab vedotin and pembrolizumab as a perioperative therapy. Recent findings suggest this approach, utilizing two immunotherapy drugs, may significantly improve outcomes for patients undergoing cystectomy, the surgical removal of the bladder. This combination is being investigated as a way to shrink tumors before surgery and potentially eliminate microscopic disease remaining after the procedure.

Understanding Urothelial Cancer and Current Treatment Approaches

Urothelial cancer is a relatively common malignancy, with approximately 80,000 latest cases diagnosed in the United States each year. The standard treatment for patients with muscle-invasive bladder cancer typically involves radical cystectomy, often combined with neoadjuvant chemotherapy (chemotherapy given before surgery). However, a significant proportion of patients still experience recurrence or progression even after this aggressive approach. This highlights the require for more effective strategies to improve long-term survival.

Enfortumab vedotin is an antibody-drug conjugate, meaning it combines an antibody that targets a protein found on bladder cancer cells with a chemotherapy drug. Pembrolizumab is a checkpoint inhibitor, a type of immunotherapy that helps the body’s immune system recognize and attack cancer cells. Combining these two agents aims to leverage different mechanisms to maximize anti-cancer activity.

Recent Trial Data: Shrinking Tumors Before Surgery

The investigation into enfortumab vedotin plus pembrolizumab centers around a phase 2 trial, the results of which are currently available as a pre-print and are undergoing peer review. The trial enrolled patients with locally advanced urothelial cancer who were candidates for radical cystectomy. Participants received enfortumab vedotin in combination with pembrolizumab for a specified period before undergoing surgery. The primary endpoint of the study was the pathological complete response (pCR) rate – meaning no cancer cells were found in the bladder and surrounding tissues after surgical removal.

Preliminary results from the trial have shown a promising pCR rate, with a substantial proportion of patients achieving a complete response before surgery. This suggests the combination therapy is effective in shrinking tumors and potentially eradicating disease. However, it’s crucial to note that these are early findings and require confirmation in larger, randomized controlled trials. The study is ongoing, and longer-term follow-up will be needed to assess the durability of these responses and the impact on overall survival.

What Does a Pathological Complete Response Mean?

A pathological complete response (pCR) is a significant finding in cancer treatment. It indicates that, after surgery, the pathology report shows no evidence of remaining cancer cells in the removed tissue. While a pCR doesn’t guarantee the cancer is completely gone—microscopic disease may still exist—it is strongly associated with improved long-term outcomes and a lower risk of recurrence. Achieving a pCR is often a primary goal of neoadjuvant therapy, as it can increase the chances of cure.

Safety Considerations and Potential Side Effects

As with any cancer treatment, enfortumab vedotin and pembrolizumab can cause side effects. Common side effects associated with enfortumab vedotin include peripheral neuropathy (nerve damage causing pain, numbness, or tingling in the hands and feet), skin reactions, and fatigue. Pembrolizumab can cause immune-related adverse events, where the immune system attacks healthy tissues. These events can affect various organs, including the lungs, liver, and intestines. Careful monitoring and management of side effects are essential during treatment. The trial data indicates that the combination was generally manageable, but further investigation into the safety profile is ongoing.

The Role of Biomarkers and Personalized Medicine

Researchers are also exploring the potential role of biomarkers—measurable substances in the body—to predict which patients are most likely to benefit from enfortumab vedotin plus pembrolizumab. Identifying biomarkers could assist personalize treatment decisions and ensure that patients receive the therapies most likely to be effective for their specific cancer. For example, the expression levels of certain proteins on cancer cells or the presence of specific genetic mutations may influence response to the combination therapy. This area of research is still evolving, but it holds promise for improving treatment outcomes.

Contextualizing the Findings: Existing Immunotherapy Approaches

The use of immunotherapy in urothelial cancer has already seen advancements. Pembrolizumab is currently approved as a first-line treatment for patients who are not eligible for cisplatin-based chemotherapy. However, the combination with enfortumab vedotin represents a novel approach, aiming to enhance the immune response and improve the effectiveness of surgery. The National Cancer Institute provides comprehensive information on bladder cancer treatment options, including immunotherapy: https://www.cancer.gov/types/bladder. The ongoing trials are designed to determine if this combination can outperform existing standards of care and offer a more durable benefit for patients.

What Comes Next: Ongoing Trials and Future Directions

The current phase 2 trial is serving as a foundation for larger, randomized phase 3 trials, which are essential to definitively establish the efficacy and safety of enfortumab vedotin plus pembrolizumab as perioperative therapy. These trials will compare the combination to standard neoadjuvant chemotherapy followed by cystectomy. The results of these trials will be crucial in determining whether this approach becomes a new standard of care for patients with locally advanced urothelial cancer. Researchers are investigating other combinations of immunotherapy and targeted therapies to further improve outcomes in this challenging disease. The American Cancer Society offers updates on cancer research and clinical trials: https://www.cancer.org/. Further research will also focus on identifying biomarkers to predict response and personalize treatment strategies.